STEPP for the EGFR inhibitor-induced rash--definitely a step in the right direction.
Coleman
Shawnta
S
Department of Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.
Jatoi
Aminah
A
D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects; D015179:Colorectal Neoplasms / Q000188:drug therapy*; D003879:Dermatologic Agents / Q000627:therapeutic use*; D003875:Drug Eruptions / Q000209:etiology / Q000517:prevention & control*; D004643:Emollients / Q000627:therapeutic use; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D005076:Exanthema / Q000139:chemically induced / Q000517:prevention & control; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D000077544:Panitumumab; D011292:Premedication; D011788:Quality of Life; D013473:Sunscreening Agents / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D003879:Dermatologic Agents; D004643:Emollients; D005938:Glucocorticoids; D013473:Sunscreening Agents; D000077544:Panitumumab; D066246:ErbB Receptors